What Wegovy Actually Costs in 2026 — Every Price, Honestly

We won't pretend otherwise: the price is the scariest part of Wegovy for most people, and the sticker number you see online — around $1,349 a month — is genuinely alarming. The good news is that the sticker price and the price you actually pay are usually two very different things. Below is every real path to a lower cost, with the exact figures pulled from Novo Nordisk's own NovoCare and Wegovy.com pages as of July 2026.

The three numbers that matter

Wegovy price at a glance

Here is how the main ways to pay stack up. Prices are per month (a 28-day supply) and reflect Novo Nordisk's published rates in July 2026.

The list price — and why almost nobody pays it

Wegovy's official list price is $1,349.02 per package, which works out to about $1,349 a month for both the injection pen and the newer pill. That is the number the pharmaceutical industry calls the "list" or "cash" price before any insurance, rebate, or manufacturer discount. It exists mostly as a starting point for negotiations between drugmakers and insurers — very few people write a check for the full amount, because Novo Nordisk itself now offers much cheaper direct-pay routes.

Paying cash: the NovoCare self-pay price

If you don't have insurance coverage for Wegovy, the cheapest official route is buying directly from Novo Nordisk's own pharmacy, NovoCare Pharmacy. The self-pay prices there are:

• Injection pen — $349 a month for the 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses. New patients pay an introductory $199 a month for their first two fills (0.25 mg and 0.5 mg), an offer running through December 31, 2026.
• Higher-dose "HD" 7.2 mg pen — $399 a month.
• Oral Wegovy (the pill) — $149 a month for the 1.5 mg dose.

If you have commercial insurance: the savings card

The lowest possible price comes from stacking two things: a commercial (employer or marketplace) insurance plan that covers Wegovy, plus Novo Nordisk's savings card. With both, you can pay as little as $25 a month. The important limits, straight from the terms:

• The savings card caps out at $100 in savings per month — so it lowers your copay, but only up to that ceiling.
• It only works with commercial insurance. If your plan doesn't list Wegovy as covered, the card can't help.
• People with government insurance — Medicare, Medicaid, TRICARE — are excluded from the savings card by law.

Because coverage is the make-or-break factor here, it's worth checking your own plan's drug list before anything else. Our GLP-1 insurance coverage guide walks through how to find out whether yours covers it.

Medicare and Medicaid: the honest reality

This is where a lot of people get stuck. A 2003 federal law (part of the Medicare Modernization Act) bars Medicare Part D from covering any drug used mainly for weight loss. That statutory exclusion still stands, so Medicare does not cover Wegovy for weight loss alone.

There are two real exceptions:

• Cardiovascular coverage. Since the FDA cleared Wegovy in March 2024 to reduce the risk of heart attack and stroke in adults with heart disease who are overweight or obese, Part D plans can cover it for that heart-protection use — because in that case it's classified as a cardiovascular drug, not a weight-loss drug.
• The Medicare GLP-1 Bridge. Novo Nordisk lists a temporary program offering eligible Medicare patients Wegovy for $50 a month, which it says began July 1, 2026. If you're on Medicare, ask your plan or check Wegovy.com whether you qualify.

Medicaid is decided state by state. Covering weight-loss drugs is optional for states, so some Medicaid programs pay for Wegovy and many do not. Your state's Medicaid drug list is the only way to know for sure.

What actually drives your out-of-pocket cost

Once you strip away the sticker shock, four things decide what you'll really pay:

• Whether your plan covers it at all. This is the single biggest factor. Covered plus savings card can mean $25; not covered means the $349 cash route.
• Commercial vs. government insurance. Commercial plans unlock the savings card; Medicare and Medicaid don't.
• Pen vs. pill. The oral form is currently the cheapest cash option at $149 a month.
• Timing of introductory offers. The $199 cash pen rate and the $50 Medicare bridge are time-limited, so today's price may not be next year's.

How Wegovy's cost compares to Zepbound and compounded options

Wegovy isn't the only GLP-1 medication, and cost is a fair reason to compare. Its main rival, Zepbound (tirzepatide), is sold direct-to-patient through LillyDirect as single-dose vials: $299 a month for the 2.5 mg dose, $399 for 5 mg, and $449 for the 7.5 mg and higher doses, per Lilly's pricing page. So on cash self-pay, Wegovy's pen ($349 for all standard doses) and Zepbound's vials ($299–$449 depending on dose) land in a similar range. Our Zepbound vs. Wegovy comparison covers how they differ beyond price.

You may also see much cheaper "compounded semaglutide" advertised — sometimes a few hundred dollars for several months. Here's the honest update: the FDA declared the semaglutide shortage resolved on February 21, 2025, and the legal window that let pharmacies mass-produce copies closed shortly after (April 22, 2025 for most compounding pharmacies and May 22, 2025 for larger outsourcing facilities). Novo Nordisk has since pursued legal action against telehealth companies still selling compounded versions. The upshot: the era of cheap, widely available compounded semaglutide has largely ended, and remaining offers carry real safety and legal uncertainty. Our compounded vs. brand semaglutide guide lays out the tradeoffs.

References

1. NovoCare — Wegovy Cost, Coverage & Savings Resources
2. NovoCare — Wegovy Savings Offer Program (self-pay and savings card terms)
3. Wegovy.com — What to Pay for Wegovy (Novo Nordisk)
4. Eli Lilly — Zepbound Cost Information (self-pay vial pricing)
5. U.S. FDA — Declaratory Order: Resolution of Semaglutide Injection Product Shortage (Feb 21, 2025)
6. ASPE / U.S. HHS — Medicare Coverage of Anti-Obesity Medications